Calcitonin

← Back to Lab Reference Library

Category: Advanced & Specialty  |  Also known as: Serum Calcitonin, Thyrocalcitonin

1. What This Test Measures

Calcitonin is a 32-amino acid polypeptide hormone produced by the parafollicular C cells of the thyroid gland. Physiologically, calcitonin acts as a short-term hypocalcemic hormone: when serum calcium rises acutely, calcitonin is released to inhibit osteoclast-mediated bone resorption, increase renal calcium excretion, and reduce intestinal calcium absorption. In adult humans with intact parathyroid function, calcitonin is a relatively minor regulator of calcium compared to parathyroid hormone and vitamin D. Patients who undergo total thyroidectomy, losing all calcitonin production, show no significant long-term calcium dysregulation.

The primary clinical value of serum calcitonin is as a tumor marker for medullary thyroid carcinoma (MTC). MTC arises from the C cells and produces calcitonin in large quantities; it is used for initial diagnosis, surgical planning, post-operative surveillance, and detection of recurrence. Calcitonin testing is also indicated in thyroid nodule evaluation, in first-degree relatives of patients with MTC or Multiple Endocrine Neoplasia type 2 (MEN2), and whenever the clinical picture raises concern for a calcitonin-secreting process.

2. Reference Ranges and Clinical Thresholds

Serum Calcitonin	Interpretation
Below 5 pg/mL (females) / Below 10 pg/mL (males)	Normal: low MTC risk; no further workup indicated in low-risk patients
10 to 100 pg/mL	Borderline to mildly elevated: investigate for benign causes; consider stimulation testing; endocrinology consultation
Above 100 pg/mL	Significantly elevated: high specificity for MTC or C-cell hyperplasia; urgent endocrinology referral and imaging
Above 500 pg/mL	Markedly elevated: consistent with advanced or metastatic MTC; surgical oncology involvement required

Calcitonin reference intervals are sex-dependent and assay-dependent. Results should always be interpreted against the specific laboratory reference range. A single mildly elevated result should be repeated with appropriate dietary and medication restrictions before clinical action is taken.

3. Medullary Thyroid Carcinoma: Why This Marker Matters

MTC accounts for approximately 3 to 4% of all thyroid cancers but causes a disproportionate share of thyroid cancer-related mortality because it does not concentrate radioiodine, limiting treatment options compared to differentiated thyroid cancers. MTC exists in two forms: sporadic (approximately 75% of cases) and hereditary (approximately 25%, occurring as part of MEN2A, MEN2B, or familial MTC, all driven by germline RET proto-oncogene mutations).

Calcitonin is the defining tumor marker for MTC. Baseline calcitonin below 10 pg/mL virtually excludes MTC. Values above 100 pg/mL have high specificity for MTC or extensive C-cell hyperplasia. Stimulation testing with intravenous calcium increases sensitivity for early MTC when baseline values are borderline. Post-surgical calcitonin normalization to undetectable levels confirms curative resection; persistent or rising post-operative calcitonin indicates residual, recurrent, or metastatic disease.

4. Non-Oncological Causes of Elevated Calcitonin

• Chronic kidney disease: renal clearance is a major elimination route for calcitonin; GFR below 40 mL/min significantly reduces clearance, producing mild to moderate elevations unrelated to MTC; always assess renal function when calcitonin is borderline elevated
• Hypercalcemia: calcium is a direct physiological stimulus for calcitonin secretion; any sustained hypercalcemia (from hyperparathyroidism, vitamin D toxicity, or malignancy) will raise calcitonin; correcting the hypercalcemia normalizes calcitonin
• Proton pump inhibitor (PPI) use: PPIs raise gastrin levels, and gastrin stimulates calcitonin secretion from C cells; chronic PPI users often show calcitonin values in the borderline range; retest after PPI discontinuation when clinically feasible
• Hashimoto thyroiditis: active autoimmune thyroiditis can mildly elevate calcitonin through inflammatory C-cell stimulation; check TPO antibody status alongside calcitonin in the borderline range
• Smoking: smoking significantly elevates calcitonin, likely through nicotinic receptor stimulation of C cells; values in active smokers may be 2 to 3 times higher than in non-smokers
• Pregnancy and neonatal period: calcitonin is naturally elevated in neonates and in some stages of pregnancy; interpret accordingly

5. Calcitonin in Comprehensive Thyroid Evaluation

Patients with Hashimoto thyroiditis, thyroid nodules discovered incidentally on imaging, or a family history of thyroid cancer benefit from baseline calcitonin measurement as part of a comprehensive thyroid workup. In Europe, thyroid guidelines recommend routine calcitonin alongside ultrasound in all nodule evaluations. U.S. practice is more selective, but the argument for including calcitonin in high-risk patients is clinically sound: MTC detected at stage I has a 10-year survival above 95%, while stage IV MTC has a 10-year survival below 20%. Early detection via calcitonin screening is the primary lever available to change that outcome.

At The Lamkin Clinic, calcitonin is measured as part of the extended thyroid panel in patients with nodules, positive family history, or symptoms suggesting a catecholamine-secreting process, and in patients with borderline thyroid antibody status who are being followed longitudinally.

6. Related Lab Tests

7. Clinical Perspective

8. Frequently Asked Questions